Ignite Creation Date:
2025-12-25 @ 3:55 AM
Ignite Modification Date:
2025-12-26 @ 2:46 AM
Study NCT ID:
NCT05218902
Status:
COMPLETED
Last Update Posted:
2023-05-31
First Post:
2022-01-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-02-25
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-20
Completion Date Type:
ACTUAL
First Submit Date:
2022-01-20
First Submit QC Date:
None
Study First Post Date:
2022-02-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-26
Last Update Post Date:
2023-05-31
Last Update Post Date Type:
ACTUAL